Attometrics Overview
- Status
-
Private
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$149K
- Investors
-
3
Attometrics General Information
Description
Developer of single-molecule diagnostics technology designed for the treatment of infectious diseases. The company's patented technology quickly detects proteins, DNA, and metabolites of interest in much smaller amounts than is possible with current methods and other bacterial strains that produce deadly Shiga toxin proteins, enabling physicians to detect biomarkers to identify potential cancers and infectious diseases.
Contact Information
Website
www.biomarker-diagnostics.com
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Biotechnology
Other Industries
Diagnostic Equipment
Primary Office
- 15013 South
- 24th Way
- Phoenix, AZ 85048
- United States
+1 (480) 000-0000
Attometrics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Grant | 01-Jan-2016 | $149K | 0000 | Completed | Startup | |
| 1. Accelerator/Incubator | 19-Nov-2012 | 0000 | 0000 | Completed | Startup |
Attometrics Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Wayne Frasch | Founder & Chief Executive Officer |
Attometrics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| National Institutes of Health | Government | 000 0000 | 000000 0 | ||
| U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 | ||
| ASU Venture Catalyst | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |